News & Therapies

Opdivo® (nivolumab) & Yervoy® (ipilimumab) April, 2025 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First‑Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma Based on the Phase 3 CheckMate‑9DW trial,...

TEVIMBRA March, 2025 TEVIMBRA added to NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers and Gastric Cancer. Objective To inform the Solid Tumor team of recent updates to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines...

March, 2025 BeiGene unveils proposed name change to BeOne Medicines, reaffirming its mission to unite the global community against cancer. New name reflects the company’s bold vision to eradicate cancer by harnessing the transformative power of global collaboration...

IMFINZI (durvalumab) January, 2025 IMFINZI Now available for the treatment of adult patients with limited-stage small cell lung cancer (LS‑SCLC) whose disease has not progressed following concurrent platinum‑based chemotherapy and radiation therapy (cCRT). To download...

Itovebi (inavolisib) November, 2024 NOW APPROVED • In combination with palbociclib and fulvestrant • For 1L HR+/HER2- mBC • With PIK3CA mutation and endocrine resistance Indication Itovebi (inavolisib), in combination with palbociclib and fulvestrant, is indicated for...

TECENTRIQ HYBREZA (atezolizumab/hyaluronidase-tqjs) November, 2024 Genentech is pleased to announce that TECENTRIQ HYBREZA is FDA approved as the first subcutaneous checkpoint inhibitor, which means a faster atezolizumab administration option is now available for you...

TEVIMBRA (tislelizumab-jsgr) October, 2024 Please review the update from BeiGene below to announce WAC pricing and that the Centers for Medicare and Medicaid Services (CMS) has assigned a permanent drug-specific J-code TEVIMBRA (tislelizumab-jsgr) injection, for...

IMFINZI (durvalumab) September, 2024 The US Food and Drug Administration (FDA) has approved a new indication for IMFINZI® (durvalumab) in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as...

Pembrolizumab September, 2024 Treatment for Adult Patients With Primary Advanced or Recurrent Endometrial Carcinoma KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the...

Voranigo September, 2024 VORANIGO was approved by the FDA to treat mIDH glioma. Please review the information and trial highlights below. Click here for this update!